TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07844148: A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of GNR-139 in Comparison With Eylea® (114.3 mg/mL) in Patients With nAMD

Sponsor: AO GENERIUM · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 180 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,806,590

Rescue Site Savings

+$7,789,410

Unlock Full NCT07844148 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07844148 Rescue Dossier →